发明名称 |
Injectable flowable composition comprising buprenorphine |
摘要 |
<p>The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.</p> |
申请公布号 |
GB2513267(B) |
申请公布日期 |
2015.03.18 |
申请号 |
GB20140013064 |
申请日期 |
2010.06.08 |
申请人 |
RB PHARMACEUTICALS LIMITED |
发明人 |
RICHARD NORTON;ANDREW WATKINS;MINGXING ZHOU |
分类号 |
A61K9/00;A61K31/485;A61K47/34 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|